Novo Nordisk Diabetes Medications

Novo Nordisk shares drop

Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.

STAT · 1d

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Yahoo Finance · 1d

Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.

1don MSN

Why Novo Nordisk Stock Is Falling Today

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Compound versions of weight loss drugs will no longer be available, FDA rules

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

1don MSN

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Reuters6d

Novo Nordisk to explore how GLP-1 drugs can help patients with addiction

GLP-1 drugs on the market include Novo Nordisk's diabetes drug Ozempic, its weight-loss treatment Wegovy and Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound. But the class of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results